ONX-0914 (ONX0914，PR-957|supplier DC Chemicals

Cas No.:	960374-59-8
Chemical Name:	(S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide
Synonyms:	ONX 0914; ONX0914; ONX-0914; PR-957
SMILES:	C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)OC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C)NC(=O)CN4CCOCC4
Formula:	C₃₁H₄₀N₄O₇
M.Wt:	580.28
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Description of ONX 0914: ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity For the constitutive proteasome. Recent evidence suggests that the immunoproteasome regulates the production of several inflammatory cytokines, including Tumor Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6), IL-17, and IL-23. In preclinical models of rhematoid arthritis and lupus, ONX 0914 blocked progression of these diseases at well-tolerated doses. Preclinical studies are underway to evaluate the potential of ONX 0914 in the treatment of a range of autoimmune disorders. For the detailed information about the solubility of ONX-0914 in water, the solubility of ONX-0914 in DMSO, the solubility of ONX-0914 in PBS buffer, the animal experiment（test） of ONX-0914,the in vivo,in vitro and clinical trial test of ONX-0914,the cell experiment（test） of ONX-0914,the IC50, EC50 and Affinity of ONX-0914, please contact DC Chemicals.

Cat. No.	Product name	Field of application
DC29221	PTP1B-IN-9	PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity.
DC11125	TCH-165	TCH-165 is a specific small molecule modulator of proteasome assembly, regulates the dynamic equilibrium between the 20S and 26S proteasome complexes, favoring 20S-mediated protein degradation.
DC10304	RA190	RA190, a bis-benzylidine piperidon, inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor RPN13.
DC4243	ONX-0914	ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.
DC5086	Ixazomib(MLN2238)	MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.
DC80430	Chlorohexane-PEG-clozapine	Chlorohexane-PEG-clozapine is a HaloTag PROTAC degrader based on Clozapine. Chlorohexane-PEG-clozapine leads to a significant decrease in the luminescence intensity and protein level of Halo-Eluc. (Pink: Ligands for Target Protein for PROTAC Target protein ligand; Blue: Ligands for E3 Ligase ligand ; Black: linker).
DC80157	Adenosine receptor antagonist 7	Adenosine receptor antagonist 7 is an orally active triple A1/A2A/A2B adenosine receptor antagonist with Ki values of 1.5, 0.6 and 21 nM. Adenosine receptor antagonist 7 shows potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells. Adenosine receptor antagonist 7 can enhance infiltration of effector T cells and increase the CD8+/Treg ratio companied with Avelumab. Adenosine receptor antagonist 7can be used for the research of cancer, such as colon cancer.
DC80120	7-APDB hydrochloride	7-APDB hydrochloride is a benzofuran compound and can be used for the research of neurological disease.
DC79698	Bortezomib	Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
DC79015	LXE408 fumarate	LXE408 fumarate is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 fumarate has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 fumarate has a low propensity to cross the blood brain barrier. LXE408 fumarate has the potential for visceral leishmaniasis (VL) research.